An update on the pharmacotherapy for lower urinary tract dysfunction

Nitya E. Abraham, Howard B. Goldman

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction: The lower urinary tract (LUT) stores and evacuates urine. It is controlled by autonomic, somatic and sensory innervation. Pharmacotherapy has been developed to optimize neural control of the LUT in pathologic states.

Areas covered: The bladder can be overactive or underactive. For overactive bladder, medications targeting various receptors include i) antimuscarinics, ii) mixed-action drugs, iii) β-adrenergic receptor agonists and iv) other medications. There is no effective pharmacotherapy for underactive bladder, although medications have been used with limited success, including i) muscarinic receptor agonists, ii) anticholinesterase inhibitors and iii) α-adrenergic receptor antagonists. At the level of the outlet, there can be decreased resistance resulting in stress urinary incontinence (SUI) or increased resistance resulting in bladder outflow obstruction (BOO). The classes of medications for SUI include i) α-adrenergic receptor agonists, ii) β-adrenergic receptor agonists and iii) antidepressants. Medications used to treat BOO include i) α-adrenergic receptor antagonists, ii) 5-α reductase inhibitors, iii) benzodiazepines, iv) baclofen and v) PDE inhibitors.

Expert opinion: Pharmacotherapy for the LUT must be individualized based on degree of bother, medication side-effect profile, concomitant comorbidities, current medication regimen, and insurance coverage. This review describes current medical therapies for the LUT.

Original languageEnglish (US)
Pages (from-to)79-93
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Urinary Tract
Adrenergic Agonists
Urinary Bladder
Drug Therapy
Adrenergic Antagonists
Stress Urinary Incontinence
Muscarinic Agonists
Overactive Urinary Bladder
Baclofen
Muscarinic Antagonists
Insurance Coverage
Cholinesterase Inhibitors
Expert Testimony
Muscarinic Receptors
Benzodiazepines
Antidepressive Agents
Comorbidity
Oxidoreductases
Urine
Pharmaceutical Preparations

Keywords

  • Bladder outflow obstruction
  • Iatrogenic obstruction
  • Overactive bladder
  • Pharmacotherapy
  • Stress urinary incontinence
  • Underactive bladder
  • Urgency incontinence

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

An update on the pharmacotherapy for lower urinary tract dysfunction. / Abraham, Nitya E.; Goldman, Howard B.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 1, 01.01.2015, p. 79-93.

Research output: Contribution to journalArticle

@article{79d8e26af4634da69c4ee5d0ab42f8ea,
title = "An update on the pharmacotherapy for lower urinary tract dysfunction",
abstract = "Introduction: The lower urinary tract (LUT) stores and evacuates urine. It is controlled by autonomic, somatic and sensory innervation. Pharmacotherapy has been developed to optimize neural control of the LUT in pathologic states.Areas covered: The bladder can be overactive or underactive. For overactive bladder, medications targeting various receptors include i) antimuscarinics, ii) mixed-action drugs, iii) β-adrenergic receptor agonists and iv) other medications. There is no effective pharmacotherapy for underactive bladder, although medications have been used with limited success, including i) muscarinic receptor agonists, ii) anticholinesterase inhibitors and iii) α-adrenergic receptor antagonists. At the level of the outlet, there can be decreased resistance resulting in stress urinary incontinence (SUI) or increased resistance resulting in bladder outflow obstruction (BOO). The classes of medications for SUI include i) α-adrenergic receptor agonists, ii) β-adrenergic receptor agonists and iii) antidepressants. Medications used to treat BOO include i) α-adrenergic receptor antagonists, ii) 5-α reductase inhibitors, iii) benzodiazepines, iv) baclofen and v) PDE inhibitors.Expert opinion: Pharmacotherapy for the LUT must be individualized based on degree of bother, medication side-effect profile, concomitant comorbidities, current medication regimen, and insurance coverage. This review describes current medical therapies for the LUT.",
keywords = "Bladder outflow obstruction, Iatrogenic obstruction, Overactive bladder, Pharmacotherapy, Stress urinary incontinence, Underactive bladder, Urgency incontinence",
author = "Abraham, {Nitya E.} and Goldman, {Howard B.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1517/14656566.2015.977253",
language = "English (US)",
volume = "16",
pages = "79--93",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - An update on the pharmacotherapy for lower urinary tract dysfunction

AU - Abraham, Nitya E.

AU - Goldman, Howard B.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction: The lower urinary tract (LUT) stores and evacuates urine. It is controlled by autonomic, somatic and sensory innervation. Pharmacotherapy has been developed to optimize neural control of the LUT in pathologic states.Areas covered: The bladder can be overactive or underactive. For overactive bladder, medications targeting various receptors include i) antimuscarinics, ii) mixed-action drugs, iii) β-adrenergic receptor agonists and iv) other medications. There is no effective pharmacotherapy for underactive bladder, although medications have been used with limited success, including i) muscarinic receptor agonists, ii) anticholinesterase inhibitors and iii) α-adrenergic receptor antagonists. At the level of the outlet, there can be decreased resistance resulting in stress urinary incontinence (SUI) or increased resistance resulting in bladder outflow obstruction (BOO). The classes of medications for SUI include i) α-adrenergic receptor agonists, ii) β-adrenergic receptor agonists and iii) antidepressants. Medications used to treat BOO include i) α-adrenergic receptor antagonists, ii) 5-α reductase inhibitors, iii) benzodiazepines, iv) baclofen and v) PDE inhibitors.Expert opinion: Pharmacotherapy for the LUT must be individualized based on degree of bother, medication side-effect profile, concomitant comorbidities, current medication regimen, and insurance coverage. This review describes current medical therapies for the LUT.

AB - Introduction: The lower urinary tract (LUT) stores and evacuates urine. It is controlled by autonomic, somatic and sensory innervation. Pharmacotherapy has been developed to optimize neural control of the LUT in pathologic states.Areas covered: The bladder can be overactive or underactive. For overactive bladder, medications targeting various receptors include i) antimuscarinics, ii) mixed-action drugs, iii) β-adrenergic receptor agonists and iv) other medications. There is no effective pharmacotherapy for underactive bladder, although medications have been used with limited success, including i) muscarinic receptor agonists, ii) anticholinesterase inhibitors and iii) α-adrenergic receptor antagonists. At the level of the outlet, there can be decreased resistance resulting in stress urinary incontinence (SUI) or increased resistance resulting in bladder outflow obstruction (BOO). The classes of medications for SUI include i) α-adrenergic receptor agonists, ii) β-adrenergic receptor agonists and iii) antidepressants. Medications used to treat BOO include i) α-adrenergic receptor antagonists, ii) 5-α reductase inhibitors, iii) benzodiazepines, iv) baclofen and v) PDE inhibitors.Expert opinion: Pharmacotherapy for the LUT must be individualized based on degree of bother, medication side-effect profile, concomitant comorbidities, current medication regimen, and insurance coverage. This review describes current medical therapies for the LUT.

KW - Bladder outflow obstruction

KW - Iatrogenic obstruction

KW - Overactive bladder

KW - Pharmacotherapy

KW - Stress urinary incontinence

KW - Underactive bladder

KW - Urgency incontinence

UR - http://www.scopus.com/inward/record.url?scp=84917705503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917705503&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.977253

DO - 10.1517/14656566.2015.977253

M3 - Article

C2 - 25351368

AN - SCOPUS:84917705503

VL - 16

SP - 79

EP - 93

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 1

ER -